<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196309</url>
  </required_header>
  <id_info>
    <org_study_id>79/09-02-2018</org_study_id>
    <secondary_id>427/01-06-2018</secondary_id>
    <nct_id>NCT04196309</nct_id>
  </id_info>
  <brief_title>Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization</brief_title>
  <acronym>LOW-RAO</acronym>
  <official_title>A Prospective, Randomized, Open-label Study to Evaluate the Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the LOW-RAO study is to determine the most effective treatment for radial
      artery occlusion (RAO) after transradial coronary catheterization (both angiography and PCI).
      This is a prospective, single-center, randomized controlled, open-label study that will
      randomize patients with RAO into two groups, one receiving anticoagulation with
      low-molecular-weight-heparin (LMWH) and the other receiving no anticoagulation. RAO will be
      detected by radial artery ultrasound up to 24 hours after the procedure.

      Study objectives:

        1. Primary objective:

           a. To evaluate the effect of treatment with LMWH, in patients (both symptomatic and
           asymptomatic) with RAO after a coronary catheterization procedure (both angiography and
           percutaneous coronary intervention-PCI), in improving patency rates of the radial artery
           at 1 month after the procedure, compared with no-LMWH treatment.

        2. Secondary objectives:

             1. To compare RAO as defined by different methods (pulse palpation, modified Allen's
                test, reverse Barbeau test, radial artery ultrasound).

             2. To compare local access site and systemic complications (bleeding events,
                pseudoaneurysm, arteriovenous fistula) at 1 month after the procedure in the LMWH
                and no-LMWH groups.

             3. To evaluate RAO incidence in coronary angiography and PCI groups.

             4. To determine risk factors for RAO in coronary catheterization procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of the radial artery as an access site for coronary catheterization procedures, is
      constantly increasing because of lower rate of access site complications, shorter hospital
      stay, improved patient comfort and safe hemostasis. Radial artery occlusion remains a concern
      after transradial procedures, with a varied incidence, ranging from 5 to 38% as reported in
      the literature and probably reflecting different evaluation methods (pulse palpation versus
      ultrasound).

      Although perceived as usually asymptomatic, registry data report that RAO may be symptomatic
      in up to 58.8% of patients, presenting as pain in the forearm, numbness/ paresthesia, paresis
      or acute ischemia. Moreover RAO excludes the affected vessel from future catheterization
      procedures, hemodialysis shunts, invasive hemodynamic monitoring, coronary arterial bypass
      grafting.

      Spontaneous recanalization of the vessel after RAO ranges from 5.4 to 47% at 1-month follow
      up. Today there is no evidence-based therapy, in the frame of a randomized control study, for
      the treatment of RAO. Heparinization has been found to be effective in reducing the
      occurrence of radial artery occlusion and short-term treatment with low-molecular-weight
      heparin (LMWH) in symptomatic patients increases the patency rate of the radial artery after
      coronary catheterization procedures, without increasing bleeding complications, as depicted
      by registry data.

      This is a prospective, randomized, multicenter study that will enroll, after informed written
      consent, all consecutive patients presenting with RAO, after a coronary catheterization
      procedure (both angiography and PCI) through the transradial access and having successfully
      received at least one radial artery sheath of any size at the end of the procedure.

      RAO will be diagnosed by radial artery ultrasound (2D, Doppler, colour) performed in all
      patients after sheath removal and successful local hemostasis and before hospital discharge.
      Clinical evaluation of radial artery patency with pulse palpation, modified Allen's test and
      reverse Barbeau test will be also applied in all patients.

      Patients diagnosed with RAO will be randomized 1:1 into two groups:

        1. Treatment group, that will receive LMWH (tinzaparin) for 1 month (at
           body-weight-adjusted therapeutic dose).

        2. Control group, that will not receive additional LMWH. All asymptomatic patients, with
           patent radial artery at initial work-up, will be provided with the opportunity to return
           to the center for further evaluation, clinically and by ultrasound, if they become
           symptomatic at any time after hospital discharge, in order to diagnose late RAO.

      They will also be provided with the opportunity to be randomized to LMWH or not in case RAO
      is diagnosed and after informed written consent.

      Patients already on anticoagulation for any other reason will neither be excluded nor
      randomized, but will be followed-up as the randomized ones, in order to collect data from
      this patient population.

      All patients with RAO will be re-evaluated by radial artery ultrasound at 1-, 2- 4- weeks to
      determine radial artery patency and record any bleeding complications according to the EASY
      (Early Discharge After Transradial Stenting of Coronary Arteries) Hematoma Classification and
      the BARC (Bleeding Academic Research Consortium) bleeding definition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radial artery patency</measure>
    <time_frame>1 month</time_frame>
    <description>To evaluate the effect of treatment with LMWH, in patients (both symptomatic and asymptomatic) with RAO after a coronary catheterization procedure (both angiography and percutaneous coronary intervention-PCI), in improving patency rates of the radial artery at 1 month after the procedure, compared with no-LMWH treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>1 month</time_frame>
    <description>To compare bleeding events (based on the BARC bleeding definition) at 1 month after the procedure between the LMWH and no-LMWH groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAO incidence</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate RAO incidence in coronary angiography and PCI groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at the forearm</measure>
    <time_frame>1 month</time_frame>
    <description>To compare incidence of pain at any region of the forearm at 1 month after the procedure between the LMWH and no-LMWH groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Arterial Occlusion</condition>
  <arm_group>
    <arm_group_label>Tinzaparin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin</intervention_name>
    <description>LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)</description>
    <arm_group_label>Tinzaparin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (both male and female) undergoing a coronary catheterization procedure (both
             angiography and PCI) through the transradial access and having successfully received
             at least one radial artery sheath of any size at the end of the procedure.

          -  Radial artery occlusion confirmed by ultrasound (2D, Doppler, colour)

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Unable to provide informed written consent

          -  Any contraindication to receive LMWH.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonios Ziakas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Cardiology Department, University General Hospital AHEPA, Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthaios V. Didagelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Cardiology Department, University General Hospital AHEPA, Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthaios V. Didagelos, MD</last_name>
    <phone>+302310994830</phone>
    <email>manthosdid@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>1st Cardiology Department, University General Hospital AHEPA</name>
      <address>
        <city>Thessalon√≠ki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthaios V Didagelos, MD</last_name>
      <phone>+302310994830</phone>
      <email>manthosdid@yahoo.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Matthaios Didagelos</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>radial artery occlusion</keyword>
  <keyword>coronary catheterization</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

